Collectively, these findings indicate that NPPDT‐56MESS functions as a chemotherapeutic agent and cGAS‐STING pathway agonist, representing a combination chemotherapy and immunotherapy strategy that provides novel modalities for the treatment of uveal melanoma. The gene discussed is STING1; the disease is uveal melanoma.